Clinical trial · Observational
Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation
Survival Benefit of Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation: A Multicenter Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are: * Is local therapy performed before or after target therapy would provide survival benefit ? * What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| before or after target therapy | Other | — | UNRESOLVED |
| Surgery or Radiotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- target therapy + local therapy group vs target therapy alone group
- interventionNames
- Other: Surgery or Radiotherapy
- label
- local therapy before target therapy group vs local therapy after target therapy group
- interventionNames
- Other: before or after target therapy
Primary outcomes (1)
- measure
- OS
- timeFrame
- From date of first follow-up until the date of documented death from any cause, assessed up to 120 months
- description
- Overall survival
Secondary outcomes (1)
- measure
- PFS
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Evidence of pathological diagnosis of primary tumor. 2. Brain metastases confirmed by enhanced magnetic resonance imaging. 3. Gene test indicated that EGFR mutation. 4. Complete clinical information. Exclusion Criteria: 1. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery. 2. Patients with 2 or more types of tumors. 3. Incomplete clinical information.
References
Publications (0)
Data not yet available